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Primary aldosteronism (PA) is the most common potentially curable form of hypertension. The 1 
overproduction of aldosterone leads to an increased risk of cardiovascular and cerebrovascular 2 
events as well as adverse effects to the heart and kidney and psychological disorders. PA is mainly 3 
caused by unilateral aldosterone excess due to an aldosterone-producing adenoma or bilateral 4 
excess due to bilateral adrenocortical hyperplasia. The diagnostic work-up of PA comprises three 5 
steps: screening, confirmatory testing and differentiation of unilateral surgically-correctable forms 6 
from medically treated bilateral PA. These specific treatments can mitigate or reverse the increased 7 
risks associated with PA. Herein we summarise the prevalence, outcomes and current and future 8 
clinical approaches for the diagnosis of primary aldosteronism.  9 
  10 
 2 
A) Introduction 11 
Primary aldosteronism (PA) is an endocrine form of hypertension first described by Jerome Conn in 12 
1955 in a young woman with an adrenocortical adenoma [1]. The characteristic features of PA are 13 
hypertension, overproduction of aldosterone and suppressed plasma renin. Once thought to be a rare 14 
disease with hypokalaemia a requisite for pursuing diagnostic work up, it is now widely accepted 15 
that PA is the most common form of endocrine hypertension with the majority of patients 16 
displaying normokalaemia [2]. Patients with PA have an increased risk of cardiovascular and 17 
cerebrovascular events, heart [3-8] and renal disease [7,9-13], diabetes, metabolic syndrome [8,14-18 
17] and a reduced quality of life [18-21]. These observations highlight the importance of an early 19 
diagnosis and appropriate treatment of PA which can reversed by specific surgical or medical 20 
treatment.  21 
 22 
The aldosterone excess originates from one or both adrenal glands (unilateral or bilateral PA) and 23 
may be caused by germline variants or arise sporadically [22,23]. The sporadic forms of PA 24 
predominate causing over 95-99% of all diagnosed cases of PA and are mainly due to a unilateral 25 
aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH, also called idiopathic 26 
hyperaldosteronism) [23]. Rarer forms of sporadic PA include unilateral adrenal hyperplasia (or 27 
primary adrenal hyperplasia) and the very rare aldosterone-producing carcinomas [24]. 28 
 29 
The optimal treatment for patients with unilateral PA is laparoscopic unilateral adrenalectomy, 30 
patients with bilateral PA are usually treated medically with a mineralocorticoid receptor (MR) 31 
antagonist. It is therefore essential that unilateral surgically-treatable forms of PA are accurately 32 
differentiated from bilateral PA. The recommended approach to differentiate unilateral from 33 
bilateral PA and to identify the adrenal for surgical resection is adrenal venous sampling (AVS) 34 
[25] although computed tomography (CT) is more widely used mainly due to technical difficulties 35 
and associated costs of AVS. The Endocrine Society clinical practice guideline for the management 36 
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of PA recommends three phases in the diagnostic work up of PA which comprise screening, 37 
confirmatory testing, and subtype differentiation [26].  38 
B) Prevalence 39 
Following the initial clinical description of PA, additional cases of PA were rapidly recognized 40 
[27]. At that time, PA was considered a rare disease comprising < 1% of patients with hypertension 41 
[28]. A screening test for PA was developed to measure the plasma aldosterone-to-renin ratio 42 
(ARR) [29] and the wider application of this screening test to include normokalaemic patients with 43 
hypertension in addition to those with hypokalaemia [30-32] resulted in a 5-15 fold increase in 44 
detection rates [2].  45 
 46 
Prevalence of PA in populations with hypertension 47 
Considerable variations have been reported in estimates of the prevalence of PA in populations with 48 
hypertension, partly due to the heterogeneity of the investigated population [33]. The prevalence of 49 
PA in the general population with hypertension was estimated as 2.6-12.7% [7,30,34-43], 50 
increasing with the severity of hypertension [7,35] and rising to 20% in patients with resistant 51 
hypertension [44]. Studies which assessed the incidence of PA according to hypertension grade 52 
reported a prevalence of 2.0-6.6% in grade I hypertension, 8.0-15.5% in grade II, and 11.8-19% in 53 
grade III [7,35,45]. The PATO (Primary Aldosteronism in TOrino) study prospectively screened a 54 
large cohort of 1672 unselected patients with hypertension in primary care using stringent 55 
diagnostic criteria and reported a prevalence of 5.9% of patients with a diagnosis of overt PA [7]. In 56 
the PATO study cohort, patients with bilateral disease comprised 65% of the total patients 57 
diagnosed with PA compared with 27% with unilateral PA; 8% had an undetermined subtype 58 
(unilateral vs. bilateral) because these patients either refused AVS or the AVS results were 59 
inconclusive [7]. The wide variance in the reported prevalence of PA in patients with hypertension 60 
in different studies is shown in Table 1.  61 
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 62 
In a study on screening for PA in 14 specialized hypertension centres, a conclusive diagnosis was 63 
made in 1125 of 1180 (95.3%) consecutively visited patients with hypertension. Unilateral APA 64 
was diagnosed in 54 of 1125 (4.8%) and BAH was found in 72 of 1125 (6.4%) patients. The use of 65 
AVS for subtype differentiation identified a higher prevalence of APA than BAH (62.5% vs 37.5%, 66 
P = 0.002) [45]. Käyser et al. [33] systematically reviewed 39 studies comprising 42510 patients 67 
with 36614 patients from hypertension units (26 studies) and 5896 patients from primary care 13 68 
studies) and reported a prevalence of PA in hypertension referral centres ranging from 0.7% to 69 
29.8% and from 3.2% to 12.7% in primary care. An additional 9 studies on the prevalence of PA in 70 
referred patients have since been published [33,46-54], bringing the median prevalence of PA in 71 
55045 referred patients with hypertension in all 36 studies to date to 7.0%. 72 
 73 
Prevalence of PA in special populations 74 
The Endocrine Society Clinical Guideline recommends screening for PA in patients with 75 
hypertension and obstructive sleep apnoea (OSA) because this category of patients appears to 76 
display a particularly high incidence of PA [26]. In a study on newly referred patients with 77 
hypertension, 34% of 53 patients with moderate-to-severe OSA were diagnosed with PA compared 78 
with an estimated frequency of 10% among patients with hypertension without sleep disorders [55]. 79 
A similar prevalence of PA (diagnosed by an elevated ARR) of 30% of 343 patients with OSA was 80 
reported in another study which identified 343 OSA affected patients from 3428 patients with 81 
hypertension [56]. It should be noted that polysomnography was not used to confirm OSA in all 82 
patients in the above studies which were also not designed from the outset to investigate the 83 
frequency of PA in patients with OSA and hypertension, thereby limiting the interpretation of 84 
results. In an ongoing prospective study aimed to evaluate the prevalence of PA in OSA patients, a 85 
diagnosis of OSA was confirmed in 91 patients by polysomnography [57]. Of these, 20.9% of 91 86 
patients were diagnosed with PA with a salt infusion test (SIT) compared with 7.3% (8 of 109) in 87 
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the group without OSA (P = 0.005). The incidence of PA was still relatively higher when patients 88 
with resistant hypertension were excluded. An elevated frequency of PA was shown in patients with 89 
increasing severity of OSA symptoms (severe vs. moderate OSA: 24.5% vs. 16.7%, P = 0.011) [57]. 90 
The positive correlation of PA and OSA in this prospective study underlined the necessity of 91 
screening for PA in patients with hypertension and OSA. 92 
 93 
Jerome Conn was the first to report impaired carbohydrate tolerance in patients with PA [58]. 94 
Several studies have since reported a high rate of type 2 diabetes and metabolic syndrome 95 
coincident with PA [6,14,16,17,59]. PA accounts for a significant proportion of patients in diabetic 96 
populations with hypertension, ranging from 11.3% to 14% [60-62], compared with 0.93% in the 97 
general population with diabetes reported in a multicentre cross-sectional study which 98 
consecutively screened 578 patients [63]. Available data to date were acquired from studies with 99 
either small cohort sizes or varied study methodologies, therefore large-cohort prospective 100 
investigations are required for prevalence evaluations, and more importantly, to provide evidence to 101 
determine if patients with type 2 diabetes especially with hypertension should be systematically 102 
screened for PA. 103 
 104 
The prevalence of PA in patients with adrenal incidentalomas has been evaluated in many studies, 105 
showing a median of 2% (range, 1.1-10%) [26], with a comparable prevalence in patients with 106 
unilateral and bilateral incidentalomas (4.3% vs 5.4%, P > 0.99) [64]. Therefore, the Endocrine 107 
Society Clinical Guideline recommends screening for PA in patients with incidentally discovered 108 
adrenal lesions [26]. 109 
 110 
C) Diagnosis 111 
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The higher prevalence of adverse effects in patients with PA relative to patients with EH highlights 112 
the importance for the early diagnosis of patients with PA including accurate subtype differentiation 113 
to assign the specific treatment option.  114 
 115 
 116 
Screening test 117 
Endocrine Society Clinical Practice Guideline recommends ARR screening test in patients with 118 
increased risks of PA: patients with resistant hypertension to ≥ 3 conventional antihypertensive 119 
drugs, hypertension and hypokalemia (spontaneous or diuretic induced), hypertension and an 120 
adrenal incidentaloma, hypertension and a family history of early-onset hypertension or 121 
cerebrovascular accident at age < 40 years, hypertension and sleep apnea, patients with sustained 122 
blood pressure > 150/100 mmHg, or all first-degree relatives of patients with PA [26]. In total, 123 
around 50% of the hypertensive population should be screened. 124 
 125 
It has been suggested that all patients with hypertension should be screened for PA [65]. One 126 
supporting example was a 10-fold elevated diagnostic rate of PA achieved in several hypertension 127 
units in Australia applying such policy [66]. Similarly, an increased screening intensity programme 128 
in Germany resulted in a higher diagnosis of patients with mild symptoms [67]. However, to date 129 
there is no compelling evidence to show the benefits from systematic screening considering the 130 
associated costs and burden on health systems. 131 
 132 
Before screening by the ARR test, if hypokalemia is present, it should be corrected to the normal 133 
range (around 4.0 mmol/L), and patients should be encouraged to liberalize sodium intake (≥ 5g 134 
NaCl/day) [26,68]. Antihypertensive medication including potassium-wasting or -sparing diuretics 135 
and products derived from liquorice should be withdrawn for 4 weeks. Two-week withdrawal of 136 
dihydropyridine calcium channel antagonists, angiotensin-converting enzyme inhibitors, 137 
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angiotensin receptor blockers, central α-2 agonists, β-adrenergic blockers and renin inhibitors is 138 
recommended. Verapamil, hydralazine or α-adrenergic blocker including prazosin/terazosin 139 
hydrochloride can be chosen as substitute [26,68]. However, adjustment of antihypertensive therapy 140 
is sometimes impractical and may cause severe side effects [69]. Without the replacement, 141 
interpretation of ARR is possible as long as renin remains suppressed [70]. Thus, omission of the 142 
medical discontinuity has been suggested [71]. Under such circumstances, antihypertensive 143 
treatment is only substituted when renin is not suppressed but the ARR and index of suspicion are 144 
high after the first screening [71].    145 
 146 
The assessment of the ARR is based on the measurement of plasma aldosterone concentration 147 
(PAC) and plasma renin activity (PRA) or direct renin concentration (DRC) [26]. The technique of 148 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers a new option to assess the 149 
ARR by measuring PAC and plasma renin concentration. It reached a high accuracy in 150 
differentiating patients with PA from those with EH [72,73]. 151 
 152 
Confirmatory testing 153 
There are four available confirmation tests: oral salt loading test (SLT), SIT, fludrocortisone 154 
suppression test (FST), and captopril challenge test (CCT) (summarised in Table 2). Further details 155 
are provided in the Endocrine Society Clinical Practice Guideline which recommends diagnosing 156 
PA based on ≥ 1 confirmatory tests, while patients with spontaneous hypokalemia and high PAC (> 157 
20 ng/dL or > 550 pmol/L) relative to suppressed renin below detection levels can bypass 158 
confirmatory testing [26,68].  159 
 160 
SIT and SLT are not applicable in patients with severe uncontrolled hypertension, renal 161 
insufficiency, cardiac arrhythmia or severe hypokalemia due to acute volume overload which may 162 
cause cardio-cerebrovascular events [26,74]. Because aldosterone levels increase in the upright 163 
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position in nearly all patients with bilateral PA and in up to half of patients with unilateral PA [75], 164 
the seated position instead of recumbence during saline infusion is suggested as a more effective 165 
approach [75,76]. The cut-off value for seated saline suppression testing (SSST) was determined as 166 
162 pmol/L after comparing results of FST and SSST in 100 patients with PA which attained a 167 
higher sensitivity (87%) than that of recumbent saline suppression testing (38%) without 168 
compromising specificity (94% vs 94%) [75].  169 
 170 
FST is considered as the reference standard when comparing efficacy of confirmation tests due to 171 
its high reliability [75,76]. It is nevertheless the most complicated and labour-intensive (up to 5-day 172 
hospitalization), and is thus less available than SIT and CCT in hypertension units [77]. 173 
 174 
The CCT is advantageous in terms of simplicity and absence of risk of fluid overload and 175 
hypokalemia, whereas equivocal results have been reported [78]. A study performed comparisons 176 
of three tests (SIT, CCT and FST) in 135 patients with PA and 101 patients with EH, and identified 177 
that a cut-off of post-CCT PAC (11 ng/dL) resulted in a high diagnostic accuracy (a sensitivity of 178 
90% and specificity of 90%). SIT achieved a similar sensitivity (85%) and specificity (92%) when 179 
applying an optimised cut-off of post-SIT PAC (8 ng/dL), thus supporting CCT and SIT to be 180 
feasible alternatives to FST [79]. A meta-analysis systematically reviewed 26 articles with 3686 181 
patients showed similar pooled sensitivities of CCT (87%) and SIT (85%) with that of FST (87%) 182 
though the pooled specificities were both lower than the reference test (84%, 87% and 95%, 183 
respectively) [80]. 184 
 185 
Subtype differentiation 186 
Once the diagnosis of PA is established, adrenal imaging such as computed tomography (CT) or 187 
magnetic resonance imaging (MRI) is mandatory to exclude the rare but highly malignant disease 188 
adrenal carcinoma [26]. However, subtype differentiation of unilateral from bilateral PA cannot 189 
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solely rely on adrenal imaging because of the low sensitivity for detection of micro-APA <10 mm in 190 
diameter [26] and inability to provide functional information. Many studies have reported a low rate 191 
of correct subtype differentiation by imaging alone, ranging from 50-80% in patients with confirmed 192 
PA [81-84]. Only a restricted subgroup of patients can rely on CT for subtype differentiation [26] and 193 
evidence in support of this comes from two studies which achieved an accuracy of 100% in 194 
lateralisation among young patients (aged < 35 years) with CT appearance of a large nodule > 10 mm 195 
in diameter and normal contralateral adrenal gland, marked PAC (> 30 ng/dL) and spontaneous 196 
hypokalemia [84,85].  197 
 198 
AVS is endorsed by Endocrine Society guideline to differentiate unilateral from bilateral forms 199 
[26]. Prior to AVS, adjustment of antihypertensive medications follows the same principle in ARR 200 
screening however some evidence suggests that MR antagonist therapy may be continued during 201 
AVS provided that renin values remain low [86,87].  202 
 203 
AVS without stimulation of adrenocorticotropic hormone (ACTH) is performed in the early 204 
morning after patients have stayed at least 1 h recumbence to avoid confounding posture-induced 205 
stimulation of the RAS and increase success rate under a higher stimulation level of the morning 206 
ACTH [68,88]. By contrast, in AVS employing ACTH stimulation via either constant cosyntropin 207 
infusion (50 µg/h, started 30 min before AVS) or bolus (usually 0.25 mg), the procedure time is 208 
more flexible, and a less technical-demanding sequential catheterisation can be performed, as well 209 
as avoiding the risk of allergic reaction [89-91]. However, ACTH stimulation is administered in 210 
only about 40% of referral units worldwide due to concerns of lowering lateralization [92]. It was 211 
reported in a recent study that ACTH loading during AVS irrespective of approach improved the 212 
rate of successful cannulation from 67% to 89% and decreased lateralisation indices from 62% to 213 
28%, but did not interfere the clinical and biochemical success in patients with APA [93].  214 
 215 
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Selectivity index (SI) is calculated as the ratio of cortisol in the adrenal vein and in a peripheral vein 216 
and is used to confirm adequate cannulation of adrenal veins. There is no consensus on the 217 
standardized cut-off of SI. Most specialised centres adopt SI>2 to 3 in unstimulated AVS, and >3 to 218 
5 in AVS with ACTH stimulation [89,90]. A less stringent cut-off permits higher AVS success rate 219 
though it potentially compromises specificity [94]. Instead of altering cut-off of SI, a rapid intra-220 
procedure cortisol assay can promote success rate of catheterisation from 50%-73% to 85-97% [95-221 
98], and its efficacy is currently sought by a randomized prospective study [99]. Lateralisation 222 
index (LI) is calculated by aldosterone/cortisol ratio in ipsilateral adrenal venous sample corrected 223 
by that ratio in contralateral sample. Likewise, there is a wide variety of LI cut-off value in referral 224 
centres [100], and a LI cut-off of 4 was recommended for unstimulated AVS and 2 for ACTH-225 
stimulated AVS [89,90]. In patients with their LI falling into the range of 2-4, some centres employ 226 
contralateral ratio (CLR) calculated by aldosterone/cortisol ratio of contralateral adrenal vein 227 
corrected by that ratio of peripheral vein as a complement to define co-existing contralateral 228 
suppression (cut-off: CLR ≤ 1) [68,100]. Metanephrine, produced by the adrenal medulla, circulates 229 
at a much higher concentration and is less sensitive to stress than cortisol. Because of these 230 
properties, metanephrine is a useful alternative to cortisol for establishing AVS selectivity and 231 
performs better than cortisol during procedures without ACTH stimulation [101]. Further, for APAs 232 
with co-secretion of cortisol and aldosterone, cortisol may confound the interpretation of AVS 233 
results when used for the normalisation of blood dilution in unstimulated procedures and the 234 
assessment of lateralisation [102].  235 
 236 
D) Future approaches for subtype differentiation 237 
Novel approaches have been investigated in recent years to replace or serve as a conjunction with 238 
traditional methods in lateralisation. Positron emission tomography (PET)-CT using radiotracer 11C-239 
metomidate, an inhibitor of 11β-hydroxylase and aldosterone synthase, was demonstrated as a 240 
potential non-invasive alternative to AVS [103]. The high specificity and affinity of 11C-241 
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metomidate to CYP11B enzymes permit distinguishing cortical masses from medullary masses, and 242 
dexamethasone prior to imaging increased the difference of maximum standardised uptake values 243 
between tumour and normal adrenal by 25.6% (P < 0.01) which was absent in BAH, thereby 244 
differentiating unilateral from bilateral PA [104,105]. A recent study reported that a treatment 245 
decision based on 11C-metomidate PET-CT achieved biochemical cure in 2 of 4 patients with PA 246 
[106]. Radiotracer 68Ga-Pentixafor binding to chemokine receptor 4, which is overexpressed in 247 
APA [107], may serve as another alternative as long as uptake difference between unilateral and 248 
bilateral subtypes is proven.  249 
 250 
Mutated forms of the potassium channel KCNJ5 drive aldosterone excess in a large proportion of 251 
APAs [108]. In a recent development, macrolide antibiotics have been identified which inhibit 252 
KCNJ5 mutants and blunt the expression of CYP11B2 and aldosterone production in KCNJ5-253 
mutated adrenocortical and adenoma cells in vitro and ex vivo [109,110]. A study is now dedicated 254 
to assessing the utility of the macrolide antibiotics clarithromycin and roxithromycin during AVS or 255 
the diagnostic work-up of PA to identify patients with KCNJ5-mutated APAs [111].  256 
 257 
LC-MS/MS-based peripheral venous steroid profiling has shown potential utility for the 258 
classification of unilateral and bilateral forms of PA [112-114]. The use of LC-MS/MS in this 259 
respect is likely associated to the underlying genotype of APAs which can be predicted with 92% 260 
accuracy [115].   261 
 262 
E) Outcomes of treatment 263 
The potential reversal of adverse effects associated with PA after treatment have been intensively 264 
studied. LV hypertrophy can be reversed after surgical or medical management as demonstrated by 265 
a regressed rate of LV hypertrophy and LV mass index to levels comparable with optimally treated 266 
patients with EH [116]. A lower LV mass index in surgically-treated patients with PA compared 267 
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with MR antagonist therapy one year after initiation of treatment (P = 0.024) has been reported 268 
[117]. A retrospective cohort study compared cardiovascular outcomes between 602 patients with 269 
PA treated with MR antagonists and 41853 age-matched patients with EH at ten-year follow-up and 270 
reported an excess incidence of adverse outcomes including atrial fibrillation and mortality limited 271 
to patients with sustained suppressed renin activity (<1 μg/L per h) (adjusted hazard ratio [HR] 2.83 272 
[95% CI 2.11–3.80] and 1.79 [1.14–2.80], respectively, vs EH) [118].  273 
 274 
Evaluation of atrial fibrillation in 201 surgically-treated and 195 medically-treated patients with PA 275 
compared with 40092 age- and blood pressure-matched patients with EH with mean follow-up of 8 276 
years demonstrated a higher risk in medically-treated patients with sustained renin suppression (<1 277 
μg/L per h) (adjusted HR, 2.55 [95% CI, 1.75-3.71]). In contrast, medically-treated patients with 278 
elevated renin levels and patients with surgical therapy showed similar risks of atrial fibrillation 279 
relative to patients with EH [119]. The incidence of atrial fibrillation has also been prospectively 280 
assessed in patients with EH and patients with PA treated surgically or medically after a median of 281 
11.8 years. Both univariate (90.0% vs 97.8%, P=0.002) and multivariate analyses (HR, 1.82 [95% 282 
CI, 1.08–3.08]) showed that medically treated patients displayed a lower atrial fibrillation-free 283 
survival than patients with EH, whereas a similarity of survival rates was noted in adrenalectomized 284 
patients with PA and EH with optimal treatment [120]. 285 
 286 
A large population cohort study compared (mean follow up, 5.2 years) of 2367 patients with PA 287 
with diabetes excluded with 9468 propensity score-matched patients with EH and identified that the 288 
risk of newly developed diabetes was attenuated in patients with PA treated with unilateral 289 
adrenalectomy (HR 0.60, P < 0.01, vs EH). The decreased incidence of diabetes was also shown in 290 
surgically-treated patients with APA (n=596) relative to matched patients with EH (n=3016) (HR 291 
0.61, P < 0.001). In contrast, MR antagonist therapy had no protective effect from diabetes in 292 
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patients with PA (including those with APA), and even resulted in an increased risk in patients with 293 
PA than those with EH (HR 1.16, P < 0.001) [121]. 294 
  295 
A study which retrospectively investigated renal parameters in 400 medically treated, 120 surgically 296 
treated patients with PA and 15474 age- and glomerular filtration rate-matched patients with EH 297 
showed that surgical removal of an APA mitigated the risk of chronic kidney disease to a level 298 
comparable to that in patients with EH (HR 0.71 [95% CI 0.39-1.30]). In contrast, the increased risk 299 
of chronic kidney disease was maintained in medically-treated patients with PA (HR 1.63 [95% CI 300 
1.33-1.99], vs EH) in whom the adjusted annual glomerular filtration rate continued to decline at a 301 
greater level compared with patients with EH (HR −1.6 [95% CI, -1.4 to -1.8] vs −0.9 [95% CI, -0.9 302 
to -1.0]) [122]. 303 
 304 
An international initiative using the Delphi method established a set of standardised criteria for the 305 
assessment of outcomes after surgical management of unilateral PA. The PASO (Primary 306 
Aldosteronism Surgical Outcome) study defines six different outcome levels (complete, partial and 307 
absent clinical or biochemical success). Clinical success was defined by blood pressure 308 
measurements and antihypertensive medication usage, biochemical success was determined by 309 
hormonal and biochemical parameters. Application of these criteria to an international cohort of 310 
patients determined complete clinical success in 37% and significant clinical benefits in 84% of 705 311 
patients. Partial and absent biochemical success was identified in 6% of 699 patients indicating 312 
persistent aldosteronism (or conceivably recurrence) despite successful AVS using stringent LI 313 
(ranging from 4.4 to 10) and total unilateral adrenalectomy [123]. Clinical remission (complete 314 
clinical success) after surgery can be predicted using a 25-point score developed by the PASO 315 
investigators (PASO score) based on 6 presurgical parameters (known duration of hypertension, 316 
sex, antihypertensive medication dosage, body mass index, target of organ damage and size of 317 
largest nodule at imaging). The use of the score was rendered user-friendly in an online tool (PASO 318 
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predictor) which applies an optimal cut-off of 16 points with an area under the curve of 0.839 to 319 
predict clinical remission after surgery with 79.2% accuracy (71.3% of sensitivity and 84.4% of 320 
specificity) [124]. A downloadable PASO predictor is available at: 321 
https://github.com/ABurrello/PASO-Predictor/raw/master/00 - PASO Predictor.xlsm.  322 
 323 
F) Summary and perspectives 324 
Powerful approaches for screening, confirmatory testing and lateralisation of aldosterone 325 
production have been developed for the diagnosis of PA. Despite this, PA remains underdiagnosed 326 
exposing these patients to an increased risk of cardiovascular, metabolic, renal and psychological 327 
complications. The screening of all patients with hypertension has been suggested by several 328 
experts but the increased burden on health systems warrants a cost-benefit analysis. Innovative 329 
approaches which may find an application in the future diagnostic work up of PA include molecular 330 
imaging to decrease invasive investigations, mass spectrometry to improve the specificity of the 331 
assays and harmonize the reference intervals between laboratories and macrolide antibiotics to 332 
characterize primary hyperaldosteronism linked to mutations in APAs. Adrenalectomy reverses the 333 
risk of specific complications associated with PA but medical treatment requires close surveillance 334 
for effective antagonism of the MR to avoid long-term complications. 335 
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Practice points 348 
 PA is a common endocrine cause of hypertension which can be surgically cured or treated 349 
with specific pharmacologic therapy  350 
 PA is underdiagnosed and individuals with untreated (or inappropriately treated) PA have an 351 
increased risk of cardiovascular events and target organ damage  352 
 Diagnosis of PA is achieved by a 3-step procedure comprising screening, confirmation 353 
testing and subtype differentiation 354 
 Screening is performed by assessment of the ARR in patients with a higher likelihood of PA 355 
 Confirmatory testing is necessary to demonstrate autonomous production of aldosterone  356 
 AVS is recommended to localize the overactive adrenal in patients who wish to pursue 357 
surgical treatment  358 
 AVS can be bypassed in patients with a unilateral adrenal mass (>10 mm diam) and a 359 
normal appearing contralateral gland with marked aldosterone excess and spontaneous 360 
hypokalaemia 361 
 Adrenalectomy for unilateral PA results in cure of hypertension in 37% of patients but 362 
significant clinical benefits are achieved in 84% 363 
 Titration of MR antagonist therapy to increase plasma renin levels may be an effective 364 
approach to avoid excess cardiovascular risk associated with medically-treated patients 365 
 366 
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Research agenda 367 
 Screening of all patients with hypertension maybe justified but a cost-benefit analysis is 368 
required considering the increased burden to health systems 369 
 Accurate methods to select patients with unilateral PA for adrenalectomy are needed to 370 
avoid AVS in medically-treated patients  371 
 Further research should define the utility of novel approaches such as mass spectrometry 372 
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Gordon et al (1993) [30] R PCC 52 11.5 11.5 CT/ AVS 33: 33 0 
Loh et al (2000) [34] P PCC 350 18 4.6 CT/ AVS 50: 50 37.5 
Mosso et al (2003) [35] R PCC 609 10.3 6.1 NA NA 2.7 
Omura et al (2004) [36] P PCC 1020 11.7 8.1 CT/ AVS 74: 20 24.6 
Westerdahl et al (2006) [38] P PCC 200 25 8.5 NA NA NA 
Williams et al (2006) [39] R PCC 347 19.6 3.2 NA NA Excluded 
Fogari et al (2007) [40] P PCC 3000 22.8 5.9 CT 30: 63 24.8 
Westerdahl et al (2011) [41] P PCC 200 18.0 5.5 CT/ AVS 27: 73 NA 
Monticone et al (2017) [7] P PCC 1672 13.9 5.9 CT/ AVS 27: 65 29.3 
Karashima et al (2017) [42] P PCC 82 40.2 3.7 NA NA NA 
Käyser et al (2018) [43] R PCC 343 21.6 2.6 NA NA NA 
Gordon et al (1994) [31] P RC 199 10.6 8.5 CT/ AVS 29: 35 Excluded 
Brown et al (1996) [125] P RC 74 8.1 2.7 NA NA Excluded 
Lim et al (2000) [126] R RC 465 16.6 8.8 NA NA 4.7 
Rossi et al (2002) [127] P RC 1046 12.8 6.3 CT 24: 76 NA 
Stowasser et al (2003) [128] P RC 300 19.7 18.0 CT/ AVS 28: 63 13.0 
Strauch et al (2003) [129] P RC 402 21.6 19.2 CT/ AVS 36: 42 NA 
Nishizaka et al (2005) [130] P RC 265 30.2 10.2 NA NA 40 
Douma et al (2008) [131] R RC 1616 20.9 11.3 NA NA 45.6 
Ribeiro et al (2009) [132] R RC 105 8.6 1.0 NA NA NA 
Pedrosa et al (2011) [133] P RC 125 11.2 5.6 CT 14:86 NA 
Rios et al (2011) [134] P RC 123 16.3 6.5 CT 25:75 50 
Sigurjonsdottir et al (2012) [135]  P RC 353 13.0 5.7 CT/ AVS 50:20 NA 
Sang et al (2013) [136] P RC 1656 29.8 7.1 CT/ AVS 33:26 52.5 
Galati et al (2016) [47] P RC 296 4.7 0.7 NA NA 0 
Gilani et al (2019) [54] R RC 80 10.0 10.0 NA NA NA 
APA, aldosterone-producing adenoma; AVS, adrenal venous sampling; BAH, bilateral hyperplasia; conf., confirmatory; CT, computed 
tomography; HTN, hypertension; HypoK+, hypokalaemia in patients with confirmed PA; N, number; NA, not available; P, prospective; PA, 
primary aldosteronism; PCC, primary care center; R, retrospective; RC, referral center. 
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Table 2: Characteristics of four confirmatory tests. 
Confirmatory 
test 





0.9% saline infusion 
(2 L over 4 h) 
PAC> 5-10 ng/dL (140-280 pmol/L) Simple procedure 
①Risk of fluid overload and 
hypokalemia;  
②Low sensitivity 
73-92% [80] 72-97% [80] Seated SIT 
SLT 
6 g sodium chloride 
per day for 3 days 
Urinary Aldo> 12 µg/24h (33 nmol/24h) 
or >14 µg/24h (39 nmol/24h) 
Simple procedure 
①Risk of fluid overload and 
hypokalemia;  
②Low patient reliability for 
urine collection 
NA NA NA 
FST 
0.1 mg oral 
fludrocortisone every 
6 h for 4 days 
Upright PAC> 6 ng/dL (170 pmol/L) on 
day 4 at 10:00 with PRA< 1 ng/mL/h and 
plasma cortisol less than value at 07:00 
Most reliable 
Most complicated,  
labor-intensive and costly 
NA NA NA 
CCT 
25-50 mg oral 
captopril 
Decrease in PAC≤ 30% (or ARR> 200 
pg/mL/ng/mL/h) or Aldo (≥ 8.5 ng/dL or 
≥ 240 pM) and ARR≥ 30 ng/dL/ng/mL/h 
①Simple procedure; 
②No risk of fluid 
overload and 
hypokalemia 
Possibility of equivocal results 70-100% [80] 68-95% [80] 
Application of 
optimized cut-
off of PAC 
Aldo, aldosterone; ARR, aldosterone-to-renin ratio; CCT, captopril challenge test; FST, fludrocortisone suppression test; NA, not available; PAC, plasma aldosterone concentration; PRA, plasma 
renin activity; SIT, saline infusion test; SLT, oral salt loading test. 
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